Limits...
Stanniocalcin-1 protects retinal ganglion cells by inhibiting apoptosis and oxidative damage.

Kim SJ, Ko JH, Yun JH, Kim JA, Kim TE, Lee HJ, Kim SH, Park KH, Oh JY - PLoS ONE (2013)

Bottom Line: We found that intravitreal injection of STC-1 increased the number of RGCs in the retina at days 7 and 14 after ONT, and decreased apoptosis and oxidative damage.In cultures, treatment with STC-1 dose-dependently increased cell viability, and decreased apoptosis and levels of reactive oxygen species in RGC-5 cells that were exposed to CoCl2.The expression of HIF-1α that was up-regulated by injury was significantly suppressed in the retina and in RGC-5 cells by STC-1 treatment.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam-gu, Seoul, Korea.

ABSTRACT
Optic neuropathy including glaucoma is one of the leading causes of irreversible vision loss, and there are currently no effective therapies. The hallmark of pathophysiology of optic neuropathy is oxidative stress and apoptotic death of retinal ganglion cells (RGCs), a population of neurons in the central nervous system with their soma in the inner retina and axons in the optic nerve. We here tested that an anti-apoptotic protein stanniocalcin-1 (STC-1) can prevent loss of RGCs in the rat retina with optic nerve transection (ONT) and in cultures of RGC-5 cells with CoCl2 injury. We found that intravitreal injection of STC-1 increased the number of RGCs in the retina at days 7 and 14 after ONT, and decreased apoptosis and oxidative damage. In cultures, treatment with STC-1 dose-dependently increased cell viability, and decreased apoptosis and levels of reactive oxygen species in RGC-5 cells that were exposed to CoCl2. The expression of HIF-1α that was up-regulated by injury was significantly suppressed in the retina and in RGC-5 cells by STC-1 treatment. The results suggested that intravitreal injection of STC-1 might be a useful therapy for optic nerve diseases in which RGCs undergo apoptosis through oxidative stress.

Show MeSH

Related in: MedlinePlus

Intravitreal administration of STC-1 increased the survival of retinal ganglion cells after optic nerve transection.(A) Immediately after optic nerve transection, 1 μg STC-1 or PBS was injected into the vitreous cavity of rats, and the retinas were evaluated for retinal ganglion cells (RGCs) at days 1, 7, 14, and 28. (B) The density of RGCs was significantly higher in the retinas treated with STC-1 compared to PBS-treated retinas at all time-points examined as counted by cells retrogradely labeled with DTMR dye (C). The values are presented as the mean ± SEM. Scale bars, 100 μm.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3646795&req=5

pone-0063749-g001: Intravitreal administration of STC-1 increased the survival of retinal ganglion cells after optic nerve transection.(A) Immediately after optic nerve transection, 1 μg STC-1 or PBS was injected into the vitreous cavity of rats, and the retinas were evaluated for retinal ganglion cells (RGCs) at days 1, 7, 14, and 28. (B) The density of RGCs was significantly higher in the retinas treated with STC-1 compared to PBS-treated retinas at all time-points examined as counted by cells retrogradely labeled with DTMR dye (C). The values are presented as the mean ± SEM. Scale bars, 100 μm.

Mentions: To evaluate the effect of STC-1 on survival of RGCs in vivo, we injected 1 μg STC-1 into the vitreous cavity of rats immediately after ONT. At days 1, 7, 14, and 28, the rats were sacrificed, and the retinas were evaluated for RGCs (Fig. 1A). The numbers of RGCs at days 7 and 14 were significantly greater in rats that received STC-1 compared to controls that received PBS (Fig. 1B, C); the numbers of RGCs were 1196±30/mm2 in STC-1-treated rats and 955±23/mm2 in PBS-treated rats (p<0.0001) at day 7, and 419±36/mm2 in STC-1-treated rats and 166±10/mm2 in controls (p<0.0001) at day 14. There was no difference in the numbers of surviving RGCs between the groups at day 28 after ONT.


Stanniocalcin-1 protects retinal ganglion cells by inhibiting apoptosis and oxidative damage.

Kim SJ, Ko JH, Yun JH, Kim JA, Kim TE, Lee HJ, Kim SH, Park KH, Oh JY - PLoS ONE (2013)

Intravitreal administration of STC-1 increased the survival of retinal ganglion cells after optic nerve transection.(A) Immediately after optic nerve transection, 1 μg STC-1 or PBS was injected into the vitreous cavity of rats, and the retinas were evaluated for retinal ganglion cells (RGCs) at days 1, 7, 14, and 28. (B) The density of RGCs was significantly higher in the retinas treated with STC-1 compared to PBS-treated retinas at all time-points examined as counted by cells retrogradely labeled with DTMR dye (C). The values are presented as the mean ± SEM. Scale bars, 100 μm.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3646795&req=5

pone-0063749-g001: Intravitreal administration of STC-1 increased the survival of retinal ganglion cells after optic nerve transection.(A) Immediately after optic nerve transection, 1 μg STC-1 or PBS was injected into the vitreous cavity of rats, and the retinas were evaluated for retinal ganglion cells (RGCs) at days 1, 7, 14, and 28. (B) The density of RGCs was significantly higher in the retinas treated with STC-1 compared to PBS-treated retinas at all time-points examined as counted by cells retrogradely labeled with DTMR dye (C). The values are presented as the mean ± SEM. Scale bars, 100 μm.
Mentions: To evaluate the effect of STC-1 on survival of RGCs in vivo, we injected 1 μg STC-1 into the vitreous cavity of rats immediately after ONT. At days 1, 7, 14, and 28, the rats were sacrificed, and the retinas were evaluated for RGCs (Fig. 1A). The numbers of RGCs at days 7 and 14 were significantly greater in rats that received STC-1 compared to controls that received PBS (Fig. 1B, C); the numbers of RGCs were 1196±30/mm2 in STC-1-treated rats and 955±23/mm2 in PBS-treated rats (p<0.0001) at day 7, and 419±36/mm2 in STC-1-treated rats and 166±10/mm2 in controls (p<0.0001) at day 14. There was no difference in the numbers of surviving RGCs between the groups at day 28 after ONT.

Bottom Line: We found that intravitreal injection of STC-1 increased the number of RGCs in the retina at days 7 and 14 after ONT, and decreased apoptosis and oxidative damage.In cultures, treatment with STC-1 dose-dependently increased cell viability, and decreased apoptosis and levels of reactive oxygen species in RGC-5 cells that were exposed to CoCl2.The expression of HIF-1α that was up-regulated by injury was significantly suppressed in the retina and in RGC-5 cells by STC-1 treatment.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam-gu, Seoul, Korea.

ABSTRACT
Optic neuropathy including glaucoma is one of the leading causes of irreversible vision loss, and there are currently no effective therapies. The hallmark of pathophysiology of optic neuropathy is oxidative stress and apoptotic death of retinal ganglion cells (RGCs), a population of neurons in the central nervous system with their soma in the inner retina and axons in the optic nerve. We here tested that an anti-apoptotic protein stanniocalcin-1 (STC-1) can prevent loss of RGCs in the rat retina with optic nerve transection (ONT) and in cultures of RGC-5 cells with CoCl2 injury. We found that intravitreal injection of STC-1 increased the number of RGCs in the retina at days 7 and 14 after ONT, and decreased apoptosis and oxidative damage. In cultures, treatment with STC-1 dose-dependently increased cell viability, and decreased apoptosis and levels of reactive oxygen species in RGC-5 cells that were exposed to CoCl2. The expression of HIF-1α that was up-regulated by injury was significantly suppressed in the retina and in RGC-5 cells by STC-1 treatment. The results suggested that intravitreal injection of STC-1 might be a useful therapy for optic nerve diseases in which RGCs undergo apoptosis through oxidative stress.

Show MeSH
Related in: MedlinePlus